Posterior Reversible Encephalopathy Syndrome in a Patient With SARS-CoV-2 Infection Treated With TocilizumabInternal Medicine Published on 2021-02-212022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome approved association Case report clinician Combination coronavirus coronavirus disease COVID-19 COVID-19 patient delirium Diseases effort Encephalopathy Evidence example Future Hospitalized Infection infections inhibitor management MRI neurologic occur off-label pandemic Patient patients patients with SARS-CoV-2 Pneumonia Posterior PRES Research Reversible SARS-CoV-2 SARS-COV-2 infection Symptomatic treatment Symptoms syndrome Tocilizumab tocilizumab therapy treated Treatment variety while [DOI] 10.7759/cureus.13475 PMC 바로가기 [Article Type] Internal Medicine
Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma PatientB 세포 림프종 환자에서 COVID-19에 대한 치료를 모니터링하기 위한 액적 기반 디지털 PCR에 의한 혈장 SARS-CoV-2 RNA 정량화의 유용성Case Reports Published on 2021-02-012022-09-12 Journal: Stem cell reviews and reports [Category] MERS, 진단, [키워드] absence Against anti-CD20 anti-IL6 autologous B-cell B-cell lymphoma Biomarker Cell clearance Clinical improvement complete recovery convalescent COVID-19 COVID-19 patients COVID19 Deterioration Digital digital PCR Efficacy eligible expected inflammatory markers monoclonal antibody Patient PCR plasma quantified receptor SARS-CoV-2 SARS-CoV-2 RNA slight increase subsequent suffered therapy tocilizumab therapy treated Treatment [DOI] 10.1007/s12015-020-10107-5 PMC 바로가기 [Article Type] Case Reports
Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids스테로이드에 반응하지 않는 환자의 중증 COVID-19 관련 과염증에 대한 룩소리티닙Article Published on 2021-01-012022-09-12 Journal: Acta haematologica [Category] 진단, [키워드] acute respiratory syndrome appear Chilean clinical condition clinical evolution Complete consecutive patient coronavirus Coronavirus disease-19 COVID-19 demonstrated develop discharge effective strategy Evolution hyperinflammation hyperinflammatory state Infection Inflammation JAK inhibitor janus Janus kinase/signal transducer and activator of transcription less lung lesions management mild infection nasal Nonresponder outcomes PaFi Patient patients presenting Prospective Study public health Randomized controlled trial reduced required resolved Respiratory failure ruxolitinib SARS-CoV-2 severe disease severe respiratory failure severe SARS-CoV-2 steroid Steroids subsequent therapy Tocilizumab tocilizumab therapy treated Treatment viral-induced was performed [DOI] 10.1159/000516464 PMC 바로가기 [Article Type] Article
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies코로나19에 대한 토실리주맙 요법: 피하 요법과 정맥 요법의 비교Comparative Study Published on 2020-12-012022-09-12 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단, [키워드] Administered baseline Clinical outcome contribute convalescent plasma COVID 19 COVID-19 Cytokine storm Cytokine storm syndrome demonstrated discharged disease dose Effect hospital hospitalized patient IL-6 receptor in-hospital mortality rate intravenous morbidity and mortality parameter Patient performed pro-inflammatory cytokines receiving respiratory respiratory parameter respiratory parameters resulting retrospective cohort study Seven significantly more therapy Tocilizumab tocilizumab therapy treat treated were assessed with COVID-19 [DOI] 10.1016/j.ijid.2020.09.1447 PMC 바로가기 [Article Type] Comparative Study
Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case seriesCase Series Published on 2020-11-052022-10-04 Journal: Annals of Medicine and Surgery [Category] 치료법, [키워드] Acute respiratory failure Administered administration Admission adverse effect analyzed Antibiotics antibody anticoagulation antivirals ARF Bacterial infection case sery characterized chronic Comorbidity COVID-19 COVID-19 patients COVID-19 pneumonia Critical Critically ill critically ill patients develop Dexamethasone dosage examined had more hallmark hospital hyperinflammation ICU infections intensive care interleukin-6 receptor intravenous intravenous infusion male measure mechanical ventilation mechanically ventilated mechanically ventilated patient monoclonal Mortality nine nosocomial not affect not significant outcome overall mortality oxygen support Oxygen therapy Patient Physiology Pneumonia Prevalence Prophylactic receiving Respiratory failure retrospective Safe survival rate therapy Tocilizumab tocilizumab therapy Treatment ventilated patient were recorded [DOI] 10.1016/j.amsu.2020.10.061 PMC 바로가기 [Article Type] Case Series
Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant RecipientsCOVID19 and Transplantation (R Avery, Section Editor) Published on 2020-10-232022-10-31 Journal: Current Transplantation Reports [Category] COVID-19, [키워드] absence administration Anecdotal anti-IL-1 anti-IL-6 appear bacterial superinfection baseline benefit canakinumab Case series characterized clinical benefit clinical experience cohort study Colchicine control group coronavirus disease Corticosteroid COVID-19 CRS cytokine Cytokine release syndrome Deleterious Efficacy and safety Evidence finding heterogeneity Hyperinflammatory immunomodulation immunomodulatory therapy Immunosuppression inhibitor Interpretation kidney lack limit management monoclonal NLRP3 inflammasome non-transplant patients observational study Patient pleiotropic Pneumonia randomized clinical trial RCT recent recipient reported review Safe shown Solid solid organ transplantation SOT survival therapeutic strategy tissue damage Tocilizumab tocilizumab therapy Transplant with COVID-19 [DOI] 10.1007/s40472-020-00306-x PMC 바로가기 [Article Type] COVID19 and Transplantation (R Avery, Section Editor)
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)Research article Published on 2020-10-152022-10-05 Journal: EClinicalMedicine [Category] 치료제, [키워드] Acute respiratory insufficiency Admission affected age Antiviral antivirals baseline Basic science boost C-reactive protein carried Characteristics clinical Clinical outcome clinical outcomes clinical trial Cohort collected Comorbidities Comorbidity COVID-19 COVID-19 outbreak COVID-19 research cyclosporine A demographic diabete Diabetes Mellitus Diagnosis died disease Diseases epidemiological Factor finding funding Glucocorticoids health system Hospitalized Hydroxychloroquine Hyperinflammation state hyperinflammatory phase hypertension immunosuppressants implication in-hospital mortality Inflammatory laboratory data male Mortality multivariate logistic regression multivariate model nasal swab Non-survivors observation Odds ratio Older age outcome paO2/fiO2 pathway Patient Positive test potential risk receiving reduce retrospective risk of death RT-PCR assay SARS-COV-2 infection severe COVID-19 severe COVID-19 patients significant decrease single-center Spanish subject survivor therapy Tocilizumab tocilizumab therapy Treatment [DOI] 10.1016/j.eclinm.2020.100591 [Article Type] Research article
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational studyCOVID-19 환자의 하이드록시클로로퀸 및 토실리주맙 요법 - 관찰 연구Research Article Published on 2020-08-132022-08-13 Journal: PLoS ONE [Category] COVID-19, Medicine and Health Sciences, MERS, SARS, [키워드] adjusted association Azithromycin benefit caution Chain Reaction cohort study Combination COVID-19 Critically ill critically ill patients death demonstrated discharge dose Electronic health record Electronic health records Exploratory analysis Hospitalization Hospitalized hospitalized COVID-19 patients hospitalized patient hospitalized patients Hydroxychloroquine ICU ICU Patients IL-6 inhibitor inhibitor of IL-6 Mortality New no significant difference no significant differences Observational cohort study Patient polymerase chain polymerase chain reaction positive propensity modeling randomized trials receiving reduced retrospective SARS-CoV-2 survival Tocilizumab tocilizumab therapy Treatment Trial registration USA with COVID-19 [DOI] 10.1371/journal.pone.0237693 PMC 바로가기 [Article Type] Research Article
Tocilizumab for the treatment of severe coronavirus disease 2019Research Article Published on 2020-05-102022-10-04 Journal: Journal of medical virology [Category] 진단, 치료제, [키워드] adverse event Antiviral agents cardiovascular disease Chronic kidney disease contribute coronavirus cough COVID‐19 COVID‐19 declined Diabetes Mellitus died discharged Dyspnea IL‐6 immune response improve clinical outcomes Inflammatory inflammatory markers inhibitor intensive care interquartile range invasive ventilation limitations majority male manifestation median median age oral temperature Pathogenesis Patient presenting symptoms proportion radiological improvement Randomized controlled trials reduced retrospective SARS‐CoV‐2 severe coronavirus disease Support Tocilizumab tocilizumab therapy Treatment Ventilation ventilatory support [DOI] 10.1002/jmv.25964 PMC 바로가기 [Article Type] Research Article